# Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

> **NCT04850378** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Aarhus** · enrollment: 57 (actual)

## Conditions studied

- Nephrotic Syndrome
- Thromboembolic Disease

## Interventions

- **DRUG:** Dalteparin
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT04850378
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-25
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04850378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04850378, "Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04850378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*